A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: Analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS).
A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: Analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS). J Clin Oncol. 2008 May 20; 26(15_suppl):7032.